7.57
+0.66%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Clinuvel Pharmaceuticals
Its shares trade on ASX under the ticker CUV.AX. It has been listed since 13 February 2001. In the fiscal year to 30 June 2026, it reported revenue of A$94.0m and net income of A$33.9m. At that date it held total assets of A$296.2m and shareholders' equity of A$272.9m.
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. The company is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for patients with vitiligo. Its pipeline includes research and development into a pediatric formulation of SCENESSE; SCENESSE for adult vitiligo patients; SCENESSE for adult patients with VP; products based on melanocortin analogues CUV9900 and Parvysmelanotide (VLRX001) and a range of over the counter products for general photoprotective application.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Feb 2001
- Employees
- 16
- Website
- clinuvel.com ↗
Leadership
Pay as last reported
- Prof. Jeffrey RosenfeldNon-Executive Chairman of the BoardA$91,667
- Dr. Philippe WolgenChief Executive Officer, Managing Director, Executive Director, since 2005A$3.7m
- Mr. Peter VaughanChief Financial Officer
- Mr. Lachlan HayChief Operations Officer
- Dr. Rose Quadbeck-DielSenior Vice President - Regulatory Affairs
- Dr. Dennis WrightChief Scientific Officer, since 2020A$782,613
- Ms. Antonella ColucciVice President - Commercial Affairs
- Mr. Malcolm BullHead of Australian Operations and Investor Relations
- Dr. Azza HamilaHead of Quality Assurance and Drug Safety
- Dr. Emilie RodenburgerDirector - Global Clinical Affairs
- Dr. Linda TengDirector of North American Operations
- Ms. Claire Newstead-SinclairCompany Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 2
- Social
- 61
- Governance
- 39
- Women in the workforce
- 64%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Clinuvel Pharmaceuticals Ltd possesses several strengths that contribute to its competitive advantage:
- Clinuvel offers a unique and innovative product portfolio, focused on pharmaceuticals to address severe skin disorders.
- The company has a robust R&D division, enabling it to continuously develop and improve new treatments, establishing a strong pipeline of products.
- Clinuvel has built a solid reputation in the pharmaceutical industry and has gained market recognition for its products.
- The company has established distribution channels across multiple regions, allowing it to reach a global customer base effectively.
Weaknesses
- Clinuvel Pharmaceuticals Ltd should address the following weaknesses to enhance its competitive position:
- Clinuvel's product portfolio is currently focused on a narrow niche market, which can increase vulnerability to changes in market demand and competition.
- The pharmaceutical industry is subject to strict regulatory requirements, and Clinuvel needs to remain compliant with these regulations, which may pose challenges and increase costs.
- Clinuvel relies heavily on its primary drug SCENESSE®, which may expose the company to risks associated with any setbacks or market challenges faced by this specific product.
Opportunities
- Clinuvel Pharmaceuticals Ltd can capitalize on the following opportunities to drive growth:
- Clinuvel can explore untapped geographical markets to expand its customer base and increase revenue streams.
- Strategic collaborations and partnerships with other pharmaceutical companies or research organizations can facilitate access to new technologies, resources, or expertise.
- Clinuvel can invest in the development and acquisition of new products or therapies to diversify its product portfolio and reduce dependency on a single drug.
Threats
- Clinuvel Pharmaceuticals Ltd faces the following threats that could impact its business:
- The pharmaceutical industry is highly competitive, with numerous players offering treatments for similar indications, which can impact Clinuvel's market share and profitability.
- Clinuvel operates in an environment where protecting intellectual property rights is crucial. The risk of infringement and patent expiration of its products can lead to increased competition and revenue losses.
- Regulatory requirements and policies can change, impacting the launch and market availability of Clinuvel's products. Compliance with evolving regulations demands resources and may cause delays.
- Economic downturns or fluctuations can affect consumer spending on healthcare and pharmaceutical products, potentially reducing demand for Clinuvel's offerings.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.